VERA

Vera Therapeutics, Inc. NASDAQ Listed May 14, 2021

Healthcare ·Biotechnology ·US · veratx.com

$36.59

After hrs $36.70 +0.29%

Mkt Cap $2.6B

52w Low $18.76 47.8% of range 52w High $56.05

50d MA $39.96 200d MA $35.14

P/E (TTM) -7.5x

EV/EBITDA -10.2x

P/B 3.7x

Debt/Equity 0.1x

ROE -49.6%

P/FCF -13.5x

RSI (14) —

ATR (14) —

Beta 1.17

50d MA $39.96

200d MA $35.14

Avg Volume 1.2M

About

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing M…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 26, 2026	BMO	-1.34	-1.39	-3.7%	42.35	-3.8%	-3.7%	-3.7%	-4.6%	-7.2%	-6.4%	—
Nov 5, 2025	BMO	-1.20	-1.26	-5.0%	24.10	-2.6%	+4.6%	+4.6%	+0.4%	+15.1%	+23.3%	—
Aug 5, 2025	BMO	-0.82	-1.20	-46.3%	20.64	-2.7%	-6.7%	-6.7%	-4.5%	-4.1%	-2.3%	—
May 6, 2025	BMO	-0.75	-0.81	-8.0%	22.01	-1.2%	+2.8%	+2.8%	+0.1%	-1.4%	+2.2%	—
Feb 26, 2025	BMO	-0.83	-0.72	+13.3%	27.77	+2.1%	+5.9%	+5.9%	+7.8%	+2.3%	+3.0%	—
Nov 7, 2024	BMO	-0.69	-0.85	-23.2%	49.04	-1.5%	-1.9%	-1.9%	-0.8%	-1.0%	+0.8%	—
Aug 8, 2024	BMO	-0.58	-0.62	-6.9%	35.85	-2.8%	+0.4%	+0.4%	-0.0%	+5.9%	+5.7%	—
May 9, 2024	BMO	-0.53	-0.56	-5.7%	42.33	+1.9%	-2.4%	-2.4%	-3.7%	-3.4%	+0.9%	—
Mar 20, 2024	BMO	-0.53	-0.58	-9.4%	45.33	+2.5%	-5.4%	-5.4%	-9.6%	-9.2%	-8.3%	—
Nov 9, 2023	BMO	-0.50	-0.45	+10.0%	11.51	+12.9%	+5.5%	+5.5%	+10.9%	+18.3%	+16.1%	—
Aug 10, 2023	BMO	-0.69	-0.46	+33.3%	19.64	+0.4%	-6.0%	-6.0%	-9.4%	-9.9%	-12.4%	—
May 11, 2023	BMO	-0.60	-0.80	-33.3%	7.55	+0.1%	+0.3%	+0.3%	+5.6%	+2.0%	+0.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 11	Wolfe Research	Upgrade	Peer Perform → Outperform	—	$40.25	$41.04	+2.0%	+4.4%	+2.3%	-0.7%	-0.5%	-2.3%
Mar 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.79	$39.95	-2.1%	-0.9%	-3.7%	-2.8%	-4.8%	-4.2%
Dec 19	BofA Securities	Maintains	Buy → Buy	—	$47.69	$48.24	+1.2%	+7.4%	+12.8%	+13.0%	+16.7%	+12.4%
Dec 19	JP Morgan	Maintains	Overweight → Overweight	—	$47.69	$48.24	+1.2%	+7.4%	+12.8%	+13.0%	+16.7%	+12.4%
Dec 19	Goldman Sachs	Maintains	Buy → Buy	—	$47.69	$48.24	+1.2%	+7.4%	+12.8%	+13.0%	+16.7%	+12.4%
Dec 11	Wedbush	Maintains	Neutral → Neutral	—	$44.34	$44.27	-0.2%	+3.8%	+12.3%	+11.0%	+8.9%	+9.4%
Dec 8	Evercore ISI	Maintains	Outperform → Outperform	—	$44.90	$44.88	-0.0%	+0.3%	-0.5%	-1.2%	+2.5%	+10.9%
Dec 5	TD Cowen	Maintains	Buy → Buy	—	$42.61	$43.53	+2.2%	+5.4%	+5.7%	+4.8%	+4.1%	+8.0%
Nov 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.19	$26.00	+7.5%	+14.7%	+22.8%	+28.5%	+17.3%	+17.2%
Nov 7	JP Morgan	Maintains	Overweight → Overweight	—	$25.22	$24.99	-0.9%	-4.1%	+10.0%	+17.8%	+23.2%	+12.5%
Aug 7	JP Morgan	Maintains	Overweight → Overweight	—	$19.25	$19.21	-0.2%	+2.4%	+2.8%	+4.8%	+9.8%	+14.1%
Aug 4	Wolfe Research	Downgrade	Outperform → Peer Perform	—	$20.95	$20.31	-3.1%	-2.4%	-1.5%	-8.1%	-5.9%	-5.5%
Jun 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.95	$31.74	+67.5%	+67.5%	+63.1%	+68.9%	+61.6%	+19.8%
Jun 2	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$18.95	$31.74	+67.5%	+67.5%	+63.1%	+68.9%	+61.6%	+19.8%
May 12	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$21.71	$22.48	+3.5%	+3.6%	-0.6%	-2.4%	-1.8%	-2.1%
May 7	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$22.01	$21.75	-1.2%	+2.8%	+0.1%	-1.4%	+2.2%	-2.0%
May 7	Wedbush	Maintains	Neutral → Neutral	—	$22.01	$21.75	-1.2%	+2.8%	+0.1%	-1.4%	+2.2%	-2.0%
Mar 4	JP Morgan	Maintains	Overweight → Overweight	—	$28.41	$28.06	-1.2%	+0.7%	+5.5%	+3.1%	+1.4%	-2.1%
Feb 27	Guggenheim	Maintains	Buy → Buy	—	$27.77	$28.35	+2.1%	+5.9%	+7.8%	+2.3%	+3.0%	+7.9%
Nov 8	Wedbush	Maintains	Neutral → Neutral	—	$49.04	$48.29	-1.5%	-1.9%	-0.8%	-1.0%	+0.8%	-0.1%
Nov 5	JP Morgan	Maintains	Overweight → Overweight	—	$45.17	$45.24	+0.2%	+5.6%	+6.1%	+8.6%	+6.5%	+7.7%
Oct 28	Guggenheim	Maintains	Buy → Buy	—	$41.09	$49.90	+21.4%	+15.2%	+4.6%	-1.1%	-1.7%	+6.6%
Oct 3	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$41.75	$41.66	-0.2%	-3.0%	-2.2%	-4.2%	-7.4%	-6.8%
Oct 1	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$44.20	$43.77	-1.0%	-3.1%	-5.5%	-8.4%	-7.6%	-9.5%
Sep 23	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$42.78	$42.58	-0.5%	+4.2%	+9.2%	+5.0%	+6.7%	+1.5%
Sep 16	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$37.51	$37.62	+0.3%	+6.9%	+6.7%	+7.5%	+11.9%	+14.0%
Sep 9	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$37.20	$37.38	+0.5%	+2.9%	+0.9%	+1.0%	-4.1%	+0.8%
Sep 6	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$38.16	$38.36	+0.5%	-2.5%	+0.3%	-1.6%	-1.5%	-6.6%
Sep 3	JP Morgan	Maintains	Overweight → Overweight	—	$37.82	$38.56	+2.0%	+1.4%	+1.5%	+0.9%	-1.6%	+1.2%
Aug 13	JP Morgan	Maintains	Overweight → Overweight	—	$35.84	$35.81	-0.1%	+5.9%	+5.7%	+3.9%	+5.0%	+9.9%
May 31	JP Morgan	Maintains	Overweight → Overweight	—	$36.95	$37.62	+1.8%	+2.8%	+9.0%	+6.8%	+11.4%	+2.9%
May 10	Raymond James	Maintains	Strong Buy → Strong Buy	—	$42.33	$43.14	+1.9%	-2.4%	-3.7%	-3.4%	+0.9%	-0.9%
Apr 5	Guggenheim	Maintains	Buy → Buy	—	$37.41	$37.14	-0.7%	+0.3%	+3.3%	+1.3%	+11.3%	+30.5%
Mar 27	Guggenheim	Maintains	Buy → Buy	—	$41.58	$42.33	+1.8%	+5.4%	+3.7%	+1.9%	-1.8%	-4.8%
Mar 21	Wedbush	Maintains	Neutral → Neutral	—	$45.33	$46.47	+2.5%	-5.4%	-9.6%	-9.2%	-8.3%	-3.3%
Jan 26	Wedbush	Maintains	Neutral → Neutral	—	$25.31	$27.10	+7.1%	+19.2%	+32.9%	+36.3%	+43.9%	+50.1%
Jan 26	Raymond James	Upgrade	Outperform → Strong Buy	—	$25.31	$27.10	+7.1%	+19.2%	+32.9%	+36.3%	+43.9%	+50.1%
Dec 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.98	$16.12	+0.9%	-0.3%	-0.1%	-3.8%	-2.3%	-3.9%
Nov 30	JP Morgan	Maintains	Overweight → Overweight	—	$13.35	$13.78	+3.2%	+1.5%	+3.7%	+3.9%	+1.1%	+3.7%
Nov 10	Jefferies	Upgrade	Hold → Buy	—	$11.51	$13.00	+12.9%	+5.5%	+10.9%	+18.3%	+16.1%	+14.9%
Sep 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.22	$14.95	+5.1%	+11.3%	+5.8%	-2.4%	-3.6%	-8.9%
Aug 11	Wedbush	Maintains	Neutral → Neutral	—	$19.64	$19.71	+0.4%	-6.0%	-9.4%	-9.9%	-12.4%	-12.9%
Jun 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.00	$9.01	+0.1%	-3.3%	-13.7%	+0.0%	+22.2%	+48.3%
May 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.55	$7.56	+0.1%	+0.3%	+5.6%	+2.0%	+0.5%	-2.0%
May 12	Wedbush	Maintains	Neutral → Neutral	—	$7.55	$7.56	+0.1%	+0.3%	+5.6%	+2.0%	+0.5%	-2.0%
Apr 12	JP Morgan	Maintains	Overweight → Overweight	—	$6.14	$6.25	+1.8%	+1.5%	+4.9%	+2.1%	+3.9%	+4.2%
Mar 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.26	$7.29	+0.4%	+5.0%	+2.5%	+6.9%	+4.1%	-1.8%
Jan 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.30	$7.15	-60.9%	-64.7%	-69.4%	-70.1%	-70.4%	-68.1%
Jan 4	Wedbush	Downgrade	Outperform → Neutral	—	$18.30	$7.15	-60.9%	-64.7%	-69.4%	-70.1%	-70.4%	-68.1%
Jan 4	Jefferies	Downgrade	Buy → Hold	—	$18.30	$7.15	-60.9%	-64.7%	-69.4%	-70.1%	-70.4%	-68.1%

Recent Filings

8-K · 5.02 !!! Very High

Vera Therapeutics, Inc. -- 8-K 5.02: Executive Change

Vera Therapeutics appointed Christopher Hite as a Class III Director, adding board experience that may influence strategic decisions and governance oversight for shareholders.

Mar 9

8-K

Vera Therapeutics, Inc. -- 8-K Filing

Vera Therapeutics reported positive Phase 3 ORIGIN 3 data for atacicept in IgA nephropathy, earning FDA priority review for its biologics license application, strengthening its path to potential market approval.

Feb 26

Data updated apr 27, 2026 7:31am · Source: massive.com